ABBOTT LABORATORIES — Earnings Release 2014

Jan 22, 2014

8-K 1 a14-3954_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D. C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of the*

*Securities Exchange Act of 1934*

*January 22, 2014*

Date of Report (Date of earliest event reported)

*ABBOTT LABORATORIES*

(Exact name of registrant as specified in charter)

Illinois	1-2189	36-0698440
(State or other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

*100 Abbott Park Road*

*Abbott Park, Illinois 60064-6400*

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (847) 937-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\105568\14-3954-1\task6469790\3954-1-ba.htm',USER='105568',CD='Jan 21 10:38 2014'

*Item 2.02 Results of Operations and Financial Condition*

On January 22, 2014, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2013.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as cost reduction initiatives, philanthropic contributions, costs that transferred or will be charged to AbbVie Inc. as part of the separation of Abbott’s research-based pharmaceuticals business, an interest expense adjustment to reflect Abbott’s capital structure after the separation of AbbVie Inc., tax expense adjustments for resolution of various tax positions from previous years, and separation-related and integration costs. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

*Item 9.01 Financial Statements and Exhibits*

Exhibit No.	Exhibit
99.1	Press Release dated January 22, 2014 (furnished pursuant to Item 2.02).

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105568\14-3954-1\task6469790\3954-1-ba.htm',USER='105568',CD='Jan 21 10:38 2014'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Thomas C. Freyman
Thomas C. Freyman
Executive Vice President, Finance and Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105568\14-3954-1\task6469790\3954-1-ba.htm',USER='105568',CD='Jan 21 10:38 2014'

*EXHIBIT INDEX*

Exhibit No.	Exhibit
99.1	Press Release, dated January 22, 2014 (furnished pursuant to Item 2.02).

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\105568\14-3954-1\task6469790\3954-1-ba.htm',USER='105568',CD='Jan 21 10:38 2014'